FIGURE 2 from A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer
Year: 2023
Type: other
Abstract: Correlative analysis of tumor specimens. Representative baseline biopsy (A) and on-treatment surgical resection (B) of a patient who responded to treatment. Color scheme, Yellow: CD8, Red: IgG4, White: CK7, Green: PD-L1, Magenta: PD-1, Blue: DAPI. Baseline biopsy demonstrates PD-L1 signal and minimal CD8 infiltration, with no detectable PD-1 or IgG4 signal, while on-treatment biopsy demonstrated diffuse CD8 infiltration colocalized with strong IgG4 signal (double positive = orange), along with minimal PD-1 signal, consistent with the visualization of the IgG4 antibody nivolumab saturating the PD-1 receptor on infiltrating T cells.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4386091449